Clinical Development of Therapeutic Anti-IgD mAb

IMT Business & Product in Development

Our business goal is to advance the humanized anti-IgD mAb to human clinical trials as a first-in-class, disease-modifying treatment for human chronic inflammations including autoimmune diseases, allergies, graft versus host diseases (GVHD), organ transplant rejection, chronic obstructive pulmonary diseases (COPDs), cardiovascular inflammations (atherosclerosis, myocarditis) and neuroinflammations (Strokes, Alzheimer’s and Parkinson’s diseases).

The key product and asset of IMT is a first-in-class humanized anti-IgD mAb therapeutic drug that is designed to activate our body’s immune system to engage and harness our inbuilt immune tolerance mechanisms and anti-inflammatory Th2 responses to induce long lasting disease remission.

IMT will utilize its research insights, know-how and intellectual properties (IP) in the biology of IgD and anti-IgD mAb in relevance to human diseases to design and to produce a humanized anti-IgD mAb drug that leverage on a unique combination of clinically proven therapeutic target (B cells), modes of actions (immune tolerance and anti-inflammatory Th2), and mAb biologic modality (renowned for its blockbuster successes) that differentiate anti-IgD mAb technology from the current therapeutics in the market to address their current unmet patient needs.  This technological leverage will thereby enable anti-IgD mAb a competitive edge to compete and gain market shares in the targeted market segments of early-stage refractory patients with moderate to severe autoimmune diseases, allergies, and others immune-mediated conditions who fail to respond to currently available treatments.

IMT Business Case & Investment Opportunity

IMT business model and strategic pathways aim to achieve its commercialization and business goals via licensing or strategic partnerships with major pharmaceutical and biotech companies that will fund the development of anti-IgD mAb from clinical trials to market approvals in major markets for therapeutic antibody biologics.

Autoimmune diseases, allergic reactions, and chronic inflammations affect approximately 1–15% of the global population, with increasing prevalence, substantial healthcare burdens, and profound socio impacts costing hundreds of billions of dollars annually (Miller FW, Curr. Opin. Immunol.,2023). Between 20-50% of patients fail to respond or eventually develop resistance to the currently available drug treatments. The market for therapeutic treatments of human autoimmune diseases and allergic conditions currently has a market value of >US$200 billion p.a. in sales revenues and the annual sales of the blockbuster therapeutic antibodies for these conditions exceed US$115 billion p.a. with significant unmet patient needs and growing demands for a novel therapeutic approach with better efficacy and less adverse side-effects that anti-IgD mAb technology aims to address.

Based on our market and technology assessment, anti-IgD mAb has the potential of gaining market share in the unmet medical needs segment that potentially equates to >US$5b in annual sales revenue in the current market of therapeutic antibody treatments for these human conditions if it gains regulatory and market approvals. 

IMT is currently looking for funding from family offices, investment funds, venture capitals, and accredited professional investors to advance the clinical development of our humanized anti-IgD mAb to human clinical trials.  IMT is also looking for partnerships/collaborations with existing pharmaceutical and biotechnology companies. 

IMT aims to raise US$19 million in capital to create and produce a humanized anti-IgD mAb to proceed to human trials within 2-4 years in Phase 1a/1b targeting 1-2 diseases (RA, lupus, psoriasis or IBD) in the multi-indication targets by anti-IgD mAb to assess and validate safety profile, MoA and early evidence of efficacy. IMT currently offers 10-20% of equity plus 2  seats on the Board of Directors (including CEO position) for US$19 million in capital funding and vested options (negotiable).

Market and Technology Risk Mitigations

Therapeutic anti-IgD mAb leverages on compelling pre-clinical research evidence of therapeutic efficacy and mode of actions of anti-IgD mAb treatment in clinically relevant animal models of various human autoimmune diseases and skin allergic inflammation that have been published by peer-view and recently have been confirmed and corroborated by other independent studies.

Therapeutic anti-IgD mAb is designed as a first-in-class, disease-modifying immunomodulating therapeutic mAb that leverages on renowned blockbuster success of humanized mAb biologic modality and clinically proven therapeutic targets of B cells and clinically validated MoA of immune tolerance and anti-inflammatory Th2 responses that have been clinically proven safe, effective, protective and approved in multiple human diseases.

Anti-IgD mAb targets a very large global market of >US$200 billion in annual sales with a growing demand for a new treatment with a novel therapeutic approach that differentiates anti-IgD mAb from current therapeutic mAb to address their significant unmet patient needs. This represents a significant and attractive commercial opportunity for the clinical development of anti-IgD mAb.  

Risk Assessments & Mitigations

Our therapeutic anti-IgD mAb will be designed and developed with multiple indications targeting a range of chronic inflammatory conditions to achieve its market shares and sales revenue to justify its substantial cost of clinical development.

The nature of commercial development of therapeutic anti-IgD mAb by IMT is a high-risk high-return investment venture that is intrinsic to all therapeutic drug developments.  Industry reviews showed therapeutic mAb technology has a 22-25% probability of success in market approval (Kaplan & Reichert, mAb, 2019).  Based on our market and technology assessment, IMT has developed a business and technology risk mitigation strategy to minimize the binary risk on investment due to technologically failure in human clinical trials.  Our therapeutic anti-IgD mAb leverages on unique technological advantageous features that will enable anti-IgD mAb to compete and gain market shares in a very large global market segment with significant unmet needs and demands.  To further minimize risks of investment, IMT will use its know-how, scientific insights and technological knowledge to strategically develop and design anti-IgD mAb as a platform that is adaptable to other modality platforms and enable it to be utilized for at least one therapeutic application in human.

Investing in the clinical development of therapeutic anti-IgD mAb will not only offer substantial financial returns but also support and advance our scientific research efforts to bring a potentially lifesaving treatment for a range of chronic diseases to the clinics to address the current significant unmet patient needs.

Investment in new drug development is a high risk, high costs and highly technical venture that require experienced professionals.  IMT recommends that investors seek independent scientific, investment and legal advice for all matters related to investment opportunities proposed by IMT.  For further information that may assist with due diligence and business assessment, contact IMT.

Inquiries

Contact IMT for all inquiries regarding due diligence information, IMT technology assessment, collaborations, and investment opportunities.

Note: IMT business proposals may contain ‘forward-looking’ statements. IMT investment opportunity aims at professional and sophisticated investors with understanding of the risks involved in biotechnology investment. IMT recommends that investors seek independent advice for scientific and investment matters related to IMT technology and investment opportunities. For more details and inquiries to assist with due diligence assessments, please contact IMT.